Product
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
5 clinical trials
1 indication
Indication
COVID-19Clinical trial
Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult VolunteersStatus: Completed, Estimated PCD: 2021-06-19
Clinical trial
To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.Status: Completed, Estimated PCD: 2022-07-31
Clinical trial
A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2021-08-07
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2022-07-08
Clinical trial
A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOVStatus: Completed, Estimated PCD: 2021-09-21